Traders should monitor the FDA decision on Deramiocel by August 22, 2026, which could be a major value inflection point. Despite zero revenue and widening losses, the strong cash position eliminates near-term dilution risk. The stock may react positively to the robust clinical data and regulatory progress, but investors should remain cautious about the lack of current revenue and high R&D spend.
Price Chart
Executive Summary
Capricor Therapeutics reported financial results for Q4 and full year 2025, highlighted by a strong cash position of $318.1 million following a $161.9 million public offering, but zero revenue due to the full recognition of prior milestone payments. The company's BLA for Deramiocel in Duchenne muscular dystrophy is under FDA review with a PDUFA date of August 22, 2026, supported by positive Phase 3 HOPE-3 trial data showing statistically significant benefits in cardiac and functional outcomes.
Key Financial Metrics
Key Facts
- BLA for Deramiocel under FDA review with PDUFA date of August 22, 2026
- HOPE-3 Phase 3 trial met primary (PUL v2.0, p=0.03) and key secondary (LVEF, p=0.04) endpoints
- Additional late-breaking data showed significant reduction in myocardial fibrosis (p=0.022) and 3.3% LVEF improvement in patients with baseline cardiomyopathy (p=0.017)
- Cash, cash equivalents, and marketable securities totaled $318.1 million as of December 31, 2025, up from $151.5 million in 2024
- Completed public offering generating $161.9 million in net proceeds and raised $75.1 million via ATM program
- Revenues were $0 for both Q4 and full year 2025, down from $11.1 million and $22.3 million in 2024, respectively
- Net loss widened to $30.2 million in Q4 2025 vs $7.1 million in Q4 2024; full-year net loss was $105.0 million vs $40.5 million in 2024
- Company uplisted to Nasdaq Global Select Market on March 9, 2026
Financial Impact
Revenue declined to $0 in 2025 from $22.3 million in 2024 due to completion of milestone revenue recognition; operating expenses increased to $108.1 million from $64.8 million; net loss tripled to $105.0 million. However, cash position more than doubled to $318.1 million, extending runway through 2027.
Risk Factors
- FDA may not approve Deramiocel despite positive trial data and PDUFA date
- Zero revenue stream increases dependence on future approval and commercialization success
- High operating expenses and net losses may pressure valuation if approval is delayed or denied
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255084 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | SC 13G/A | $7.27 $6.13 | ▲ +15.68% | ▲ +14.67% | $5.74 (+21.05%) |
Aug 24, 2026 9w ago | 8-K | $6.80 $9.91 | ▼ −45.74% | ▼ −45.27% | $5.74 (+15.59%) |
Aug 21, 2026 9w ago | Institutional Cluster | $6.29 $9.59 | ▲ +52.46% | ▲ +51.99% | $5.74 (−8.74%) |
Jul 30, 2026 12w ago | Press Release | $4.19 $4.18 | ▲ +0.24% | ▲ +3.86% | $5.74 (−36.99%) |
Jul 14, 2026 14w ago | 8-K | $20.35 $18.91 | ▼ −7.08% | ▼ −6.10% | $5.74 (−71.79%) |
Jun 29, 2026 17w ago | Insider Cluster | $24.08 $22.43 | ▼ −6.85% | ▼ −7.46% | $5.74 (−76.16%) |
Jun 26, 2026 17w ago | 8-K | $23.80 $22.43 | ▼ −5.76% | ▼ −7.14% | $5.74 (−75.88%) |
Jun 24, 2026 17w ago | Insider Cluster | $30.40 $23.07 | ▼ −24.11% | ▼ −25.67% | $5.74 (−81.12%) |
Jun 1, 2026 21w ago | Court Ruling | $27.34 $26.01 | ▼ −4.86% | ▼ −1.90% | $5.74 (−79.01%) |
May 12, 2026 23w ago | Press Release | $30.33 $26.92 | ▼ −11.24% | ▼ −10.09% | $5.74 (−81.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers